合成致死
氧化磷酸化
生物
背景(考古学)
癌症研究
糖酵解
生物化学
细胞生物学
突变体
酶
基因
古生物学
作者
Yuting Sun,Madhavi L. Bandi,Timothy E. Lofton,Melinda G. Smith,Christopher Aaron Bristow,Alessandro Carugo,Norma E. Rogers,Paul G. Leonard,Qing Chang,Robert A. Mullinax,Jing Dong J Han,Xi Shi,Sahil Seth,Brooke A. Meyers,Meredith A. Miller,Lili Miao,Xiaoyan Ma,Ningping Feng,Virginia Giuliani,Mary Geck
出处
期刊:Cell Reports
[Cell Press]
日期:2019-01-01
卷期号:26 (2): 469-482.e5
被引量:59
标识
DOI:10.1016/j.celrep.2018.12.043
摘要
The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity. To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo . Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP + /NADPH ratio to disrupt redox homeostasis. Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-molecule inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo . Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI